Munson Medical Center | Cancer Research Department

Research site

(Unclaimed)

Location

1105 Sixth Street, Traverse City, Michigan, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel

Carboplatin

Bevacizumab

Cisplatin

Lenalidomide

Nivolumab

Docetaxel

Gemcitabine Hydrochloride

Gemcitabine

Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 436 total trials

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participan...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Biological: Nivolumab

Drug: Cisplatin

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor D...

Enrolling

Stage III Colon Cancer

Drug: mFOLFOX6 3-6 month

Device: Signatera test

Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever (DISTALS)

The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flo...

Enrolling

Ischemic Stroke

Neovascularization

Device: Tigertriever 13

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting

Coronary Heart Disease (CHD)

Drug: Evolocumab

Drug: Placebo

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patie...

Active, not recruiting

Hormone-resistant Prostate Cancer

Stage IV Prostate Cancer

Drug: prednisone

Drug: abiraterone

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several...

Enrolling

KRAS G12C Mutation

PI3K Gene Mutation

Drug: PI3K Inhibitor paxalisib

Drug: Entrectinib

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

This randomized phase III trial compares ixazomib citrate, lenalidomide, dexamethasone and zoledronic acid with zoledronic acid alone to see how well...

Active, not recruiting

Solitary Osseous Plasmacytoma

Drug: dexamethasone

Drug: lenalidomide

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial (LeAAPS)

This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effec...

Enrolling

Ischemic Stroke

Systemic Embolism

Device: AtriClip LAA Exclusion System

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of es...

Active, not recruiting

Breast Cancer

Other: Placebo

Drug: Letrozole

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to se...

Active, not recruiting

Multiple Myeloma in Relapse

Drug: ixazomib

Drug: pomalidomide

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment o...

Enrolling

Recurrent Lung Non-Small Cell Carcinoma

Stage IV Lung Cancer AJCC v8

Biological: Pembrolizumab

Biological: Ramucirumab

S0820, Adenoma and Second Primary Prevention Trial (PACES)

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and...

Active, not recruiting

Colorectal Neoplasms

Drug: Eflornithine placebo & sulindac placebo

Drug: Eflornithine plus sulindac

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen depriva...

Active, not recruiting

Prostate Cancer

Drug: Bicalutamide

Drug: TAK-700

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenan...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Daratumumab/rHuPH20

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in pa...

Enrolling

Prognostic Stage IA Breast Cancer AJCC v8

Prognostic Stage IB Breast Cancer AJCC v8

Biological: Trastuzumab Emtansine

Other: Quality-of-Life Assessment

Locations recently updated

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyc...

Enrolling

Grade 3b Follicular Lymphoma

Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma

Drug: Cyclophosphamide

Other: Patient Observation

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy...

Active, not recruiting

Recurrent Primary Peritoneal Carcinoma

Ovarian Undifferentiated Carcinoma

Drug: Gemcitabine

Drug: Cediranib Maleate

The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System

prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in...

Active, not recruiting

Bradycardia

Cardiac Rhythm Disorder

Device: Aveir VR Leadless Pacemaker System

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension (RADIANCE-II)

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hyperte...

Active, not recruiting

Hypertension

Cardiovascular Diseases

Procedure: Renal Angiogram

Device: Paradise Renal Denervation System

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with me...

Enrolling

Recurrent Meningioma

NF2 Gene Mutation

Drug: Vismodegib

Drug: Abemaciclib